China's Venus Persists With Global TAVR Solutions Expansion
Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.
You may also be interested in...
Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.
Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology.
US firm Colibri Heart Valve and China-based Venus Medtech have formed a venture to commercialize two heart valves in China and other emerging markets: a balloon-expandable version created by Colibri and a self-expanding version developed by Venus using tissue processed by Colibri.